LONG-TERM POST-RECURRENCE SURVIVAL (PRS) OUTCOMES FOR STAGE IIB/C MELANOMA PATIENTS IN REAL-WORLD (RW) SETTINGS: ANALYSES FROM A LONGITUDINAL ELECTRONIC HEALTH RECORD DATABASE IN THE UNITED STATES

被引：0
|
作者：
Kurt, M. [1 ]
Zhang, Y. [2 ]
Srinivasan, S. [1 ]
Dyer, M. [3 ]
Moshyk, A. [1 ]
Shelley, K. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Uxbridge, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO115
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 6 条
  • [1] Outcomes From Real-World Data on Intraoperative Electronic Radiotherapy for the Treatment of Early-Stage Breast Cancer: Long-Term Recurrence and Survival Outcomes From a Single Center
    de la Mata, Dolores
    Santiago-Concha, Bernardino Gabriel
    Bargallo-Rocha, Juan Enrique
    Robles-Vidal, Carlos Daniel
    Gomez-Pue, Daniella
    Castorena-Roji, Gerardo
    Hinojosa-Gomez, Jose
    Flores-Vazquez, Fabiola
    Blake-Cerda, Monika
    Enriquez-Barrera, Mario
    Maffuz-Aziz, Antonio
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [2] Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States
    Nigo, Masayuki
    Rasmy, Laila
    May, Sarah B.
    Rao, Aishwarya
    Karimaghaei, Sam
    Kannadath, Bijun Sai
    De la Hoz, Alejandro
    Arias, Cesar A.
    Li, Liang
    Zhi, Degui
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 148 - 154
  • [3] Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.
    Coleman, Robert L.
    Shen, Qin
    Goulden, Scott
    Mathews, Cara Amanda
    Hunger, Matthias
    Pahwa, Ankit
    Schade, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] From Real-World Data to Improved Outcomes: Examining the Impact of Trastuzumab Disparities on Pathological Complete Response and Long-Term Survival in HER-2 Positive Breast Cancer Patients within the Brazilian Public Health System
    Antonini, Marcelo
    Mattar, Andre
    Pannain, Gabriel
    Richter, Fernanda Grace Bauk
    Amorim, Andressa
    Diogenes, Marina
    Ferraro, Odair
    Gebrim, Luiz
    Lopes, Reginaldo Coelho
    Real, Juliana
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database
    Kaedbey, Rayan
    Reece, Donna
    Venner, Christopher P.
    Mccurdy, Arleigh
    Su, Jiandong
    Chu, Michael
    Louzada, Martha
    Jimenez-Zepeda, Victor H.
    Mian, Hira
    Song, Kevin
    Sebag, Michael
    Stakiw, Julie
    White, Darrell
    Reiman, Anthony
    Aslam, Muhammad
    Kotb, Rami
    Bergstrom, Debra
    Gul, Engin
    Leblanc, Richard
    EJHAEM, 2024, 5 (03): : 474 - 484
  • [6] Long-Term Proteasome Inhibition in Multiple Myeloma (MM) Following an in-Class Transition (iCT) from Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the United States (US) MM-6 Community-Based Study: Subgroup Analyses of Real-World Data in Patients Aged <75 and ≥75 Years
    Birhiray, Ruemu E.
    Manda, Sudhir
    Girnius, Saulius K.
    Lyons, Roger M.
    Boccia, Ralph V.
    Jhangiani, Haresh S.
    Kambhampati, Suman
    Rifkin, Robert M.
    Bogard, Kimberly
    Whidden, Presley
    Cherepanov, Dasha
    Noga, Stephen J.
    Yimer, Habte A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S299 - S299
1